- MSI-1436, the core internal asset of Genaera, is a clinical candidate in Phase 1 development for the treatment of obesity and has applicability in type 2 diabetes. Genaera initiated its first-in-man clinical studies in 2Q07.
- MEDI-528 the second core asset out-licensed to MedImmune/Astra Zeneca is being evaluated in Phase 2 clinical studies with applicability in the treatment of asthma. Please refer to www.medimmune.com for status of this program.
